Back to Results
First PageMeta Content
ACE inhibitors / Peptide hormones / Angiotensin II receptor antagonists / Endocrinology / Enantiopure drugs / Renin inhibitor / Antihypertensive drug / Hypertension / Renin-angiotensin system / Chemistry / Medicine / Biology


Coverage Initiation Report Coverage initiated November 4th, 2014 Aurgalys is contracted by Quantum Genomics to provide equity research Quantum Genomics
Add to Reading List

Document Date: 2015-02-03 21:11:15

Open Document

File Size: 1,13 MB

Share Result on Facebook

City

Paris / Evry / Louvain / /

Company

Novartis / Figure / Sepal Pharma / Thomson / IBM Europe / Alix Asset Management / Cerep / Delore & Associés / Inserm-Transfert / Bayer / Carlson Wagonlit Travel / Grand Allied Creation Company / Quantum Genomics / Inserm Transfert Initiative / Ador Corporation / Anceris / /

Continent

Europe / Americas / Asia / North America / /

Country

France / Japan / Canada / United Kingdom / China / India / Croatia / Belgium / Russia / United States / South Korea / /

Currency

USD / EUR / /

Event

FDA Phase / Patent Filing / Dividend Issuance / /

Facility

William Harvey Research Institute / Quantum Genomics’ pipeline / Queen Mary University of London / DRUG PIPELINE / French National Institute of Health / University of Chicago / Mayo Clinic / /

IndustryTerm

pharmaceutical industry / TREATMENT OF HEART FAILURE / in-house products / age / THERAPY FOR HYPERTENSION / therapies for cardiovascular diseases / technology originating / THERAPIES FOR HYPERTENSION / stage pharmaceutical / manufacturing / technology transfer / age groups / large pharmaceutical groups / galenic and pharmaceutical form / pharmaceutical / healthcare / pharmaceutical groups / biopharmaceutical / treatment of hypertension / healthcare authorities / therapeutic solution / /

MedicalCondition

drugs preventing hypertension / ACEI QGC006 Arterial hypertension / arterial hypertension / FOR RESISTANT HYPERTENSION / cerebrovascular disease / monotherapy QGC101 Congestive heart failure / coronary heart disease / worldwide hypertension / illness / cardiovascular diseases / OF HYPERTENSION / OF HEART FAILURE / chronic high blood pressure / diagnosed hypertension / health concern Cardiovascular diseases / high blood pressure / animal heart failure / peripheral arterial disease / muscle contraction / obesity / FOR HYPERTENSION / blindness / Ethnicity Obesity November 4th / congestive heart failure / hypertension / disease / resistant hypertension / HEART FAILURE / I Phase IIa Licensing QGC001 Arterial hypertension / killer Hypertension / /

MedicalTreatment

drug targeting / /

Organization

World Health Organization / National Research Agency / French National Institute of Health / Research Organization / Paris-Sud University / William Harvey Research Institute / European Union / University of London / the University of Chicago / Mannheim Business School / Ecole Nationale / American Heart Association / Strategic Council for Innovation / Executive Committee of Bayer / /

Person

Jean-Philippe Milon / Quantum Genomics Mickael Dubourd / Christophe Dombu / Fabrice Balavoine / Lionel Ségard / Alexandre Persu / Mark Caulfield / Pierre Corvol / Marc Karako / Innovation / John Burnett Jr. / /

/

Position

president / Chief Executive Officer / Engineer / Vice President Chemistry / CEO / Executive / one of the founders / Chief Financial Officer / Legal Officer / Chef / CFO of international groups / Vice President Research & Development Fabrice Balavoine / specialist / Secretary General / Vice president Finance / Chief Operating Officer / Chairman / director / Drug Discovery Manager / Executive Vice President / Chief Executive Officer and Board’s Chairman / /

Product

Cardizem / minoxidil / metolazone / lisinopril / valsartan / Phase IIa / QGC001 / ramipril / Calan / Chlorothiazide / Cardene / furosemide / /

Technology

Drug Discovery / Genomics / Pharmacokinetics / CVD / drug development / /

URL

www.health.harvard.edu / /

SocialTag